Exagen Inc. Enhances Board with Appointment of Chas McKhann

Company - People | Jul 17, 2025 | Tullis-Dickerson & Co Inc

Exagen Inc., a prominent provider of autoimmune testing solutions, has appointed Chas McKhann to its Board of Directors, effective July 17, 2025. McKhann brings over 25 years of experience in the life sciences industry, having served in leadership roles at multiple medical technology companies. His previous positions included CEO and President at Silk Road Medical and Apollo Endosurgery, both acquired by Boston Scientific. Exagen's CEO, John Aballi, expressed excitement over McKhann joining, citing his valuable leadership in life sciences and his potential to drive growth and advance patient care. McKhann is eager to contribute to Exagen's strategic growth and enhance value for patients, providers, and shareholders. Exagen specializes in innovative testing for complex autoimmune conditions, with a focus on research, innovation, and patient care.

Sectors

Healthcare
Medical Technology

Geography

United States – Exagen Inc. is based in Carlsbad, California and is a significant provider of autoimmune testing solutions in the U.S.

Industry

Healthcare – Exagen Inc. operates within the Healthcare industry, focusing on autoimmune diagnostics and innovative testing solutions.
Medical Technology – Chas McKhann's background in medical technology companies and Exagen's focus on advanced diagnostics positions both within the Medical Technology sector.

Financials

Participants

Name	Role	Type	Description
Exagen Inc.	Target Company	Company	A provider of innovative autoimmune testing solutions focused on improving patient outcomes.
Tullis-Dickerson & Co Inc.	Private Equity Firm	Company	The private equity firm mentioned in relation to Exagen Inc.
Chas McKhann	Board Member	Person	Recently appointed to Exagen's Board of Directors with extensive experience in life sciences leadership.
John Aballi	CEO of Exagen	Person	Current President and Chief Executive Officer of Exagen Inc.